Related Experiment Videos
Opioid antagonist modulation of rat heart development
1Department of Neuroscience and Anatomy, Pennsylvania State University, M.S. Hershey Medical Center, Hershey, PA 17033.
Life Sciences
|January 1, 1994
Summary
Opioid antagonists like naltrexone significantly boost cardiac cell proliferation in young rats, suggesting opioids normally inhibit heart development. This points to potential therapeutic uses for opioid antagonists in treating congenital heart defects.
Area of Science:
- Cardiovascular Biology
- Developmental Neuroscience
- Endocrinology
Background:
- Endogenous opioids regulate morphogenesis in various biological systems.
- The role of endogenous opioids in cardiac development remains largely unexplored.
Purpose of the Study:
- To investigate the influence of endogenous opioids on cardiac development using an opioid antagonist.
- To determine if opioid signaling plays a role in regulating heart formation.
Main Methods:
- Administration of naltrexone, a potent opioid antagonist, to 1-day-old rats.
- Assessment of DNA synthesis in cardiac cells using [3H]-thymidine incorporation and autoradiography.
- Longitudinal examination of cardiac and body growth in rats exposed to naltrexone from birth.
Main Results:
- Naltrexone administration significantly increased DNA synthesis in myocardial and epicardial cells.
- Elevated labeling indices persisted for at least 12 hours post-naltrexone injection.
- Chronic naltrexone exposure led to increased body and heart weights, and larger heart and ventricular dimensions.
Conclusions:
- Endogenous opioid peptides appear to act as negative regulators of cardiac development.
- Disruptions in the endogenous opioid system during early life may contribute to cardiac dysmorphogenesis.
- Opioid antagonists show potential as a therapeutic strategy for congenital heart malformations.